- 現金殖利率: N/A、總殖利率: 0、5年平均現金配發率: N/A
- 要留意資產負債表的未分配盈餘和配息能力, 如果為負值, 可能會無法發放股利
- 股利有2個稅要支出, 分別是綜合所得稅和健保補充保費(單筆股利達2萬元以上, 課2.11%)
| EPS YoY | 現金股利 YoY | 股票股利 YoY | 現金配發率 YoY | 股票配發率 YoY | 全部配發率 YoY | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023 (10) | 2.26 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 |
| 2022 (9) | -10.28 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 |
| 2021 (8) | -3.30 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 |
| 2020 (7) | -7.82 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 |
| 2019 (6) | 0.55 | 223.53 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 |
| 2018 (5) | 0.17 | -66.67 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 |
| 2017 (4) | 0.51 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 |
| 2016 (3) | -2.07 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 |
| EPS QoQ YoY | 本業EPS QoQ YoY | 累計EPS QoQ YoY | |||||||
|---|---|---|---|---|---|---|---|---|---|
| 24Q3 (20) | 0.19 | -59.57 | -69.84 | 0.68 | -32.0 | -35.24 | 2.29 | 9.05 | 1045.0 |
| 24Q2 (19) | 0.47 | -70.99 | 2.17 | 1.00 | -55.95 | -8.26 | 2.10 | 29.63 | 588.37 |
| 24Q1 (18) | 1.62 | -21.36 | 282.02 | 2.27 | -12.36 | 940.74 | 1.62 | -28.32 | 282.02 |
| 23Q4 (17) | 2.06 | 226.98 | 227.16 | 2.59 | 146.67 | 359.0 | 2.26 | 1030.0 | 121.98 |
| 23Q3 (16) | 0.63 | 36.96 | 218.87 | 1.05 | -3.67 | 153.85 | 0.20 | 146.51 | 111.56 |
| 23Q2 (15) | 0.46 | 151.69 | 169.7 | 1.09 | 503.7 | 141.29 | -0.43 | 51.69 | 64.17 |
| 23Q1 (14) | -0.89 | 45.06 | -64.81 | -0.27 | 73.0 | 86.5 | -0.89 | 91.34 | -64.81 |
| 22Q4 (13) | -1.62 | -205.66 | -92.86 | -1.00 | 48.72 | 39.02 | -10.28 | -494.22 | -211.52 |
| 22Q3 (12) | -0.53 | 19.7 | 30.26 | -1.95 | 26.14 | 35.0 | -1.73 | -44.17 | 29.67 |
| 22Q2 (11) | -0.66 | -22.22 | 28.26 | -2.64 | -32.0 | 29.97 | -1.20 | -122.22 | 29.82 |
| 22Q1 (10) | -0.54 | 35.71 | 31.65 | -2.00 | -21.95 | 36.31 | -0.54 | 83.64 | 31.65 |
| 21Q4 (9) | -0.84 | -10.53 | -44.83 | -1.64 | 45.33 | 21.53 | -3.30 | -34.15 | 57.8 |
| 21Q3 (8) | -0.76 | 17.39 | -16.92 | -3.00 | 20.42 | -15.83 | -2.46 | -43.86 | 66.02 |
| 21Q2 (7) | -0.92 | -16.46 | 44.24 | -3.77 | -20.06 | 56.57 | -1.71 | -116.46 | 74.05 |
| 21Q1 (6) | -0.79 | -36.21 | 83.98 | -3.14 | -50.24 | 13.74 | -0.79 | 89.9 | 83.98 |
| 20Q4 (5) | -0.58 | 10.77 | -223.4 | -2.09 | 19.31 | -164.71 | -7.82 | -8.01 | -1521.82 |
| 20Q3 (4) | -0.65 | 60.61 | 0.0 | -2.59 | 70.16 | 0.0 | -7.24 | -9.86 | 0.0 |
| 20Q2 (3) | -1.65 | 66.53 | 0.0 | -8.68 | -138.46 | 0.0 | -6.59 | -33.67 | 0.0 |
| 20Q1 (2) | -4.93 | -1148.94 | 0.0 | -3.64 | -212.69 | 0.0 | -4.93 | -996.36 | 0.0 |
| 19Q4 (1) | 0.47 | 0.0 | 0.0 | 3.23 | 0.0 | 0.0 | 0.55 | 0.0 | 0.0 |
| 年/月 | 營收 | 月增率(%) | 去年同期年增率(%) | 累計營收 | 累計營收年增率(%) | 近三月累計營收 | 存貨銷售比 | 自結稅前EPS | 自結稅前累計EPS | 備註(年增率變動50%需說明原因) |
|---|---|---|---|---|---|---|---|---|---|---|
| 2024/10 | 0.87 | 11.36 | -1.43 | 8.5 | 11.09 | 2.48 | N/A | - | ||
| 2024/9 | 0.78 | -5.98 | -0.85 | 7.63 | 12.73 | 2.38 | 0.0 | - | ||
| 2024/8 | 0.83 | 8.27 | -0.39 | 6.85 | 14.51 | 2.44 | 0.0 | - | ||
| 2024/7 | 0.77 | -9.11 | -4.9 | 6.02 | 16.93 | 2.42 | 0.0 | - | ||
| 2024/6 | 0.84 | 3.9 | 7.68 | 5.25 | 20.98 | 2.5 | 0.0 | - | ||
| 2024/5 | 0.81 | -3.96 | 3.29 | 4.41 | 23.9 | 2.71 | 0.0 | - | ||
| 2024/4 | 0.84 | -19.72 | 3.83 | 3.6 | 29.73 | 2.7 | 0.0 | - | ||
| 2024/3 | 1.05 | 31.94 | 40.33 | 2.76 | 40.48 | 2.76 | 0.0 | - | ||
| 2024/2 | 0.8 | -11.85 | 27.13 | 1.7 | 40.58 | 2.91 | 0.0 | - | ||
| 2024/1 | 0.9 | -25.04 | 55.03 | 0.9 | 55.03 | 3.04 | 0.0 | 因疫情解封致營收成長 | ||
| 2023/12 | 1.21 | 30.37 | 66.17 | 9.78 | 79.09 | 3.01 | 0.0 | 因疫情解封致營收成長 | ||
| 2023/11 | 0.93 | 5.06 | 91.13 | 8.58 | 81.07 | 2.59 | 0.0 | 因疫情解封致營收成長 | ||
| 2023/10 | 0.88 | 12.01 | 89.69 | 7.65 | 79.92 | 2.5 | 0.0 | 因疫情解封致營收成長 | ||
| 2023/9 | 0.79 | -5.53 | 69.75 | 6.77 | 78.72 | 2.43 | 0.0 | 因疫情趨緩致營收成長 | ||
| 2023/8 | 0.83 | 3.36 | 71.95 | 5.98 | 79.98 | 2.42 | 0.0 | 因疫情趨緩致營收成長 | ||
| 2023/7 | 0.81 | 2.91 | 86.26 | 5.15 | 81.35 | 2.37 | 0.0 | 因疫情趨緩致營收成長 | ||
| 2023/6 | 0.78 | -0.32 | 139.22 | 4.34 | 80.46 | 2.38 | 0.0 | 因疫情趨緩致營收成長 | ||
| 2023/5 | 0.79 | -3.46 | 109.4 | 3.56 | 71.21 | 2.35 | 0.0 | 因疫情解封致營收成長 | ||
| 2023/4 | 0.81 | 8.49 | 92.36 | 2.77 | 62.81 | 2.19 | 0.0 | 因疫情解封致營收成長 | ||
| 2023/3 | 0.75 | 19.54 | 90.17 | 1.96 | 53.05 | 1.96 | 0.0 | 因疫情解封致營收成長 | ||
| 2023/2 | 0.63 | 7.49 | 47.62 | 1.21 | 36.55 | 1.94 | 0.0 | - | ||
| 2023/1 | 0.58 | -19.65 | 26.35 | 0.58 | 26.35 | 1.79 | 0.0 | - | ||
| 2022/12 | 0.73 | 49.95 | 19.2 | 5.46 | 39.47 | 1.68 | 0.0 | - | ||
| 2022/11 | 0.48 | 4.27 | 30.54 | 4.74 | 43.21 | 1.41 | 0.0 | - | ||
| 2022/10 | 0.46 | 0.23 | 31.76 | 4.25 | 44.81 | 1.41 | 0.0 | - | ||
| 2022/9 | 0.46 | -4.31 | 45.07 | 3.79 | 46.59 | 1.38 | 0.0 | - | ||
| 2022/8 | 0.48 | 11.97 | 54.54 | 3.32 | 46.8 | 1.24 | 0.0 | 因疫情趨緩致營收成長 | ||
| 2022/7 | 0.43 | 32.17 | 105.96 | 2.84 | 45.56 | 1.14 | 0.0 | 因疫情趨緩致營收成長 | ||
| 2022/6 | 0.33 | -12.75 | 160.66 | 2.41 | 38.27 | 1.13 | 0.0 | 因疫情趨緩致營收成長 | ||
| 2022/5 | 0.38 | -11.32 | 50.44 | 2.08 | 28.76 | 1.19 | 0.0 | 因疫情趨緩致營收成長 | ||
| 2022/4 | 0.42 | 7.26 | 15.62 | 1.7 | 24.8 | 1.24 | 0.0 | - | ||
| 2022/3 | 0.39 | -7.2 | 27.72 | 1.28 | 28.15 | 1.28 | 0.0 | - | ||
| 2022/2 | 0.42 | -7.99 | 30.48 | 0.89 | 28.35 | 1.5 | 0.0 | - | ||
| 2022/1 | 0.46 | -24.2 | 26.45 | 0.46 | 26.45 | 1.44 | 0.0 | - | ||
| 2021/12 | 0.61 | 64.21 | 41.89 | 3.92 | -11.23 | 1.33 | 0.0 | - | ||
| 2021/11 | 0.37 | 5.25 | 4.45 | 3.31 | -16.96 | 1.04 | 0.0 | - | ||
| 2021/10 | 0.35 | 10.36 | -6.93 | 2.94 | -19.06 | 0.99 | 0.0 | - | ||
| 2021/9 | 0.32 | 1.93 | -10.05 | 2.58 | -20.47 | 0.84 | 0.0 | - | ||
| 2021/8 | 0.31 | 49.22 | -17.32 | 2.26 | -21.75 | 0.65 | 0.0 | - | ||
| 2021/7 | 0.21 | 67.28 | -36.85 | 1.95 | -22.42 | 0.58 | 0.0 | - | ||
| 2021/6 | 0.13 | -49.64 | -42.0 | 1.74 | -20.22 | 0.74 | 0.0 | - | ||
| 2021/5 | 0.25 | -31.84 | 60.45 | 1.61 | -17.82 | 0.92 | 0.0 | 去年本月受疫情影響致營收驟降 | ||
| 2021/4 | 0.37 | 18.48 | 215.25 | 1.37 | -24.54 | 1.0 | 0.0 | 去年本月受疫情影響致營收驟降 | ||
| 2021/3 | 0.31 | -5.2 | 77.29 | 1.0 | -40.97 | 1.0 | 0.0 | 受疫情影響致本期營收下降 | ||
| 2021/2 | 0.33 | -10.83 | -34.8 | 0.69 | -54.53 | 1.12 | 0.0 | 受疫情影響致本期營收下降 | ||
| 2021/1 | 0.37 | -14.94 | -64.19 | 0.37 | -64.19 | 1.15 | 0.0 | 受疫情影響致本期營收下降 | ||
| 2020/12 | 0.43 | 20.88 | -66.89 | 4.41 | -63.79 | 1.16 | 0.0 | 受疫情影響致本期營收下降 | ||
| 2020/11 | 0.36 | -6.21 | -65.25 | 3.98 | -63.43 | 1.09 | 0.0 | 受疫情影響致本期營收下降 | ||
| 2020/10 | 0.38 | 6.66 | -62.25 | 3.63 | -63.24 | 1.11 | 0.0 | 受疫情影響致本期營收下降 | ||
| 2020/9 | 0.36 | -6.3 | -61.93 | 3.25 | -63.35 | 1.07 | 0.0 | 受疫情影響致本期營收下降 | ||
| 2020/8 | 0.38 | 13.96 | -64.84 | 2.89 | -63.51 | 0.93 | 0.0 | 受疫情影響致本期營收下降 | ||
| 2020/7 | 0.33 | 53.64 | -65.31 | 2.51 | -63.31 | 0.7 | 0.0 | 受疫情影響致本期營收下降 | ||
| 2020/6 | 0.22 | 39.31 | -76.64 | 2.18 | -62.98 | 0.49 | 0.0 | 受疫情影響致本期營收下降 | ||
| 2020/5 | 0.16 | 33.9 | -84.56 | 1.97 | -60.43 | 0.45 | 0.0 | 受疫情影響致本期營收下降 | ||
| 2020/4 | 0.12 | -33.36 | -88.07 | 1.81 | -54.3 | 0.79 | 0.0 | 受疫情影響致本期營收下降 | ||
| 2020/3 | 0.17 | -65.13 | -84.22 | 1.69 | -43.3 | 1.69 | 0.0 | 受疫情影響致本期營收下降 | ||
| 2020/2 | 0.5 | -51.02 | -45.26 | 1.52 | -19.3 | 2.82 | 0.0 | - | ||
| 2020/1 | 1.02 | -21.37 | 5.11 | 1.02 | 5.11 | 3.34 | 0.0 | - | ||
| 2019/12 | 1.3 | 26.88 | 7.15 | 12.19 | 4.91 | 0.0 | N/A | - | ||
| 2019/11 | 1.02 | 1.88 | 1.66 | 10.89 | 4.65 | 0.0 | N/A | - |
